Reframe Daily: Simple heart-attack rehab works; new HCM pill beats beta-blocker, Replace Eyeball with Tooth To See

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A simple rehab plan after a heart attack helped older adults do better; a new pill for a thick-heart condition (HCM) beat a common beta-blocker; custom, gentle brain-stimulation eased depression in a trial; and proton radiation to the brain and spine looked safer and more precise.

Christin’s note: Oops I know this looks a bit creepy.. but it’s a remarkable surgery where a blind patient’s tooth is used to anchor a new lens that allows them to see again! The tooth allows secure placement of the lens and the patient’s body is less likely to reject it compared to a transplant. It was developed in the 1960s and still used today.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A simple, coached rehab program for seniors after a heart attack cut bad outcomes and is ready to use anywhere now.

Multidomain Rehabilitation for Older Patients with Myocardial Infarction

Market readiness: 🙂🙂🙂🙂🙂 (already deliverable in U.S. cardiac-rehab programs; no new drug or device needed). 

Good news: A heart-muscle–calming pill beat a common beta-blocker for a tough heart condition, pointing to better exercise capacity and symptoms.

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

Market readiness: 🙂🙂🙂🙂 (late-stage evidence; aficamten isn’t FDA-approved yet, but results could speed U.S. uptake once reviewed). 

Good news: Brain-stimulation tailored to a person’s brain map eased depression symptoms in a randomized trial—noninvasive and drug-free.

Personalized High-Definition Transcranial Direct Current Stimulation for Depression

Market readiness: 🙂🙂🙂 (devices exist, but depression use in the U.S. still needs regulatory clearance and larger confirmatory trials). 

Good news: A randomized trial of proton craniospinal irradiation reports clinical outcomes that support a safer, more precise way to deliver whole-axis radiation—aiming to lower side effects while maintaining control.

Proton Craniospinal Irradiation—Randomized Clinical Trial (JAMA Oncology)

Market readiness: 🙂🙂🙂🙂🙂 (proton centers already operate in the U.S.; data like this can change protocols quickly at available sites).  

Thank you for taking the time to take care of yourself and your loved ones.